There is need to do the India specific development of such tests . That is another challenge . Another issue is that the clinical validation is required and due to issues in regulatory setup , the discouragement happens within the companies who are developing such products .
The biotech industry needs to engage the medical community who generally say that they have lot of patient load and can ’ t participate in such exercises . They need to be convinced . The non communicable disease such as diabetes , cardiovascular diseases need solutions that should work for life . The government must steer the capacity strategies to ensure that the communities that are working for clinical validation get support . Ownership of the clinical trials is a must . For few patients who have no access to early products , the clinical trials are seen as a hope . The compassionate use selectively is fine .
In terms of discovery or development of molecules , it would be interesting that if Indian groups take advantage of the international funds .
Even if it is risky , it might give at least a clue if not a product . There is also a need to utilize the vast traditional knowledge to create new chemical or biological entities .
The key is to find innovative ways of generating ideas through vast network of institutes , take them to industry and get the best answer possible .
BIOVOICENEWS . COM 49